Break Up Big Medicine Act

The 'Break Up Big Medicine Act' (S.3822) was introduced in the Senate on February 10, 2026, by Senator Warren and cosponsored by Senator Hawley. It has been read twice and referred to the Committee on the Judiciary. This bill is in its early legislative stages, indicating that significant steps remain before it could become law. The bill's core mechanism is to prohibit common ownership across different segments of the healthcare supply chain, specifically targeting pharmacy benefit managers, insurers, prescription drug or medical device wholesalers, and certain medical service providers. The bill text highlights findings that large, vertically integrated healthcare platforms dominate the American healthcare system, creating inherent conflicts of interest. There is no explicit funding amount authorized or appropriated within this bill; its impact would stem from regulatory changes forcing divestiture and restructuring rather than direct financial allocation. Structural winners under this legislation could include smaller, independent biotech firms or medical service providers that might gain market share or acquisition opportunities if larger entities are forced to divest. Conversely, large, vertically integrated pharmaceutical companies and healthcare conglomerates such as Johnson & Johnson ($JNJ), Pfizer Inc. ($PFE), Merck & Co., Inc. ($MRK), Amgen Inc. ($AMGN), Gilead Sciences, Inc. ($GILD), Vertex Pharmaceuticals Incorporated ($VRTX), Biogen Inc. ($BIIB), and Regeneron Pharmaceuticals, Inc. ($REGN) could be significantly impacted. These companies, particularly those with diversified operations spanning manufacturing, distribution, and potentially PBMs or insurance arms, would face forced restructuring and divestment of assets. Looking at recent market data, over the past 7 days, Pfizer Inc. ($PFE) has seen a +0.22% change, Johnson & Johnson ($JNJ) a -0.63% change, Merck & Co., Inc. ($MRK) a +2.33% change, Amgen Inc. ($AMGN) a -1.84% change, Gilead Sciences, Inc. ($GILD) a +2.78% change, Vertex Pharmaceuticals Incorporated ($VRTX) a -2.00% change, Biogen Inc. ($BIIB) a -8.12% change, and Regeneron Pharmaceuticals, Inc. ($REGN) a +1.84% change. Over the past 30 days, Pfizer Inc. ($PFE) is up +4.58%, Johnson & Johnson ($JNJ) is up +0.56%, Merck & Co., Inc. ($MRK) is up +4.12%, Amgen Inc. ($AMGN) is down -6.81%, Gilead Sciences, Inc. ($GILD) is down -3.45%, Vertex Pharmaceuticals Incorporated ($VRTX) is down -5.75%, Biogen Inc. ($BIIB) is down -8.37%, and Regeneron Pharmaceuticals, Inc. ($REGN) is down -0.25%. The current market performance of these companies shows mixed results, with some experiencing recent gains and others declines, indicating no clear market reaction directly tied to this early-stage bill. The next legislative steps for S.3822 involve committee hearings and potential markups within the Committee on the Judiciary. If it passes out of committee, it would then proceed to a vote in the full Senate. Given its early stage, passage is not guaranteed, and the bill could undergo significant changes.